Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 12/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21823385 | 1.00 | FPR2 (0.48) | FPR2S1PR1SMN1; SMN2S1PR3PDE4B | |
| SCHEMBL31096163 | 0.93 | FPR2 (0.41) | FPR2SMN1; SMN2PDE4BNPC1MAPT | |
| SCHEMBL21823538 | 0.93 | FPR2 (0.41) | FPR2SMN1; SMN2PDE4BNPC1MAPT | |
| SCHEMBL21823604 | 0.92 | FPR2 (0.50) | FPR2PDE4B | |
| SCHEMBL31096087 | 0.92 | FPR2 (0.50) | FPR2PDE4B | |
| SCHEMBL21823737 | 0.91 | FPR2 (0.42) | FPR2S1PR1SMN1; SMN2PDE4BPDE4A | |
| SCHEMBL21823747 | 0.90 | FPR2 (0.42) | FPR2S1PR1PDE4BPDE4APDE4C | |
| SCHEMBL31096064 | 0.89 | FPR2 (0.49) | FPR2S1PR1PDE4B | |
| SCHEMBL21823424 | 0.89 | FPR2 (0.49) | FPR2S1PR1PDE4B | |
| SCHEMBL21823730 | 0.88 | FPR2 (0.44) | FPR2PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166177-B | Boron-containing PDE4 inhibitors | 辉瑞公司 | 2024-09-03 | — | — | CN | disclosed |